Longeveron (LGVN) EBT (2020 - 2026)
Longeveron (LGVN) posted quarterly EBT of -$5.5 million for Q1 2026, up 14.64% year-over-year from -$4.8 million in Q1 2025, and up 11.31% quarter-over-quarter from -$6.3 million in Q4 2025.
Longeveron (LGVN) EBT (2020 - 2026) Analysis & Trends
Longeveron's EBT history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.
- In Q1 2026, EBT rose 14.64% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$27.4 million (down 35.82% YoY), while the FY2025 annual figure was -$24.3 million, up 29.52% from the prior year.
- EBT for Q1 2026 stood at -$5.5 million, up from -$6.3 million in the prior quarter.
- The five-year high for EBT was -$3.5 million in Q2 2024, with the low at -$42.7 million in Q1 2023.
- The 5-year median for EBT is -$5.4 million (2022), against an average of -$7.7 million.
- The sharpest annual moves came in 2023 and 2024: EBT tumbled 942.87% in 2023, then soared 89.9% in 2024.
- Longeveron's EBT stood at -$5.2 million in 2022, then decreased by 4.63% to -$5.5 million in 2023, then grew by 4.11% to -$5.2 million in 2024, then dropped by 19.18% to -$6.3 million in 2025, then increased by 11.31% to -$5.5 million in 2026.
- Business Quant data shows LGVN's EBT at -$5.5 million in Q1 2026, -$6.3 million in Q4 2025, and -$8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.50 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -6.81 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -5.25 Mn |
| Sep 30, 2024 | -4.87 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -5.47 Mn |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -5.95 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -5.23 Mn |
| Sep 30, 2022 | -5.41 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |